Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia

Motonori Mizutani; Akiyoshi Takami; Masahiko Hara; Shohei Mizuno; Masamitsu Yanada; Takaaki Chou; Hitoji Uchiyama; Kazuteru Ohashi; Toshihiro Miyamoto; Yukiyasu Ozawa; Osamu Imataki; Naoki Kobayashi; Naoyuki Uchida; Heiwa Kanamori; Tomohiko Kamimura; Tetsuya Eto; Makoto Onizuka; Junji Tanaka; Yoshiko Atsuta; Shingo Yano

doi:10.1016/j.bbmt.2017.05.008

Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia

Motonori Mizutani, Akiyoshi Takami, Masahiko Hara, Shohei Mizuno, Masamitsu Yanada, Takaaki Chou, Hitoji Uchiyama, Kazuteru Ohashi, Toshihiro Miyamoto, Yukiyasu Ozawa, Osamu Imataki, Naoki Kobayashi, Naoyuki Uchida, Heiwa Kanamori, Tomohiko Kamimura, Tetsuya Eto, Makoto Onizuka, Junji Tanaka, Yoshiko Atsuta, Shingo Yano

Internal Medicine

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P =.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P =.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.

Original language	English
Pages (from-to)	1447-1454
Number of pages	8
Journal	Biology of Blood and Marrow Transplantation
Volume	23
Issue number	9
DOIs	https://doi.org/10.1016/j.bbmt.2017.05.008
Publication status	Published - Sep 2017

All Science Journal Classification (ASJC) codes

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2017.05.008

Fingerprint Dive into the research topics of 'Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia'. Together they form a unique fingerprint.

Cite this

Mizutani, M., Takami, A., Hara, M., Mizuno, S., Yanada, M., Chou, T., Uchiyama, H., Ohashi, K., Miyamoto, T., Ozawa, Y., Imataki, O., Kobayashi, N., Uchida, N., Kanamori, H., Kamimura, T., Eto, T., Onizuka, M., Tanaka, J., Atsuta, Y., & Yano, S. (2017). Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation, 23(9), 1447-1454. https://doi.org/10.1016/j.bbmt.2017.05.008

Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. / Mizutani, Motonori; Takami, Akiyoshi; Hara, Masahiko; Mizuno, Shohei; Yanada, Masamitsu; Chou, Takaaki; Uchiyama, Hitoji; Ohashi, Kazuteru; Miyamoto, Toshihiro; Ozawa, Yukiyasu; Imataki, Osamu; Kobayashi, Naoki; Uchida, Naoyuki; Kanamori, Heiwa; Kamimura, Tomohiko; Eto, Tetsuya; Onizuka, Makoto; Tanaka, Junji; Atsuta, Yoshiko; Yano, Shingo.

In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 9, 09.2017, p. 1447-1454.

Research output: Contribution to journal › Article › peer-review

Mizutani, M, Takami, A, Hara, M, Mizuno, S, Yanada, M, Chou, T, Uchiyama, H, Ohashi, K, Miyamoto, T, Ozawa, Y, Imataki, O, Kobayashi, N, Uchida, N, Kanamori, H, Kamimura, T, Eto, T, Onizuka, M, Tanaka, J, Atsuta, Y & Yano, S 2017, 'Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia', Biology of Blood and Marrow Transplantation, vol. 23, no. 9, pp. 1447-1454. https://doi.org/10.1016/j.bbmt.2017.05.008

Mizutani, Motonori ; Takami, Akiyoshi ; Hara, Masahiko ; Mizuno, Shohei ; Yanada, Masamitsu ; Chou, Takaaki ; Uchiyama, Hitoji ; Ohashi, Kazuteru ; Miyamoto, Toshihiro ; Ozawa, Yukiyasu ; Imataki, Osamu ; Kobayashi, Naoki ; Uchida, Naoyuki ; Kanamori, Heiwa ; Kamimura, Tomohiko ; Eto, Tetsuya ; Onizuka, Makoto ; Tanaka, Junji ; Atsuta, Yoshiko ; Yano, Shingo. / Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia. In: Biology of Blood and Marrow Transplantation. 2017 ; Vol. 23, No. 9. pp. 1447-1454.

@article{59797f639e354310a283a935e2a39477,

title = "Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia",

abstract = "Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P =.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P =.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.",

author = "Motonori Mizutani and Akiyoshi Takami and Masahiko Hara and Shohei Mizuno and Masamitsu Yanada and Takaaki Chou and Hitoji Uchiyama and Kazuteru Ohashi and Toshihiro Miyamoto and Yukiyasu Ozawa and Osamu Imataki and Naoki Kobayashi and Naoyuki Uchida and Heiwa Kanamori and Tomohiko Kamimura and Tetsuya Eto and Makoto Onizuka and Junji Tanaka and Yoshiko Atsuta and Shingo Yano",

year = "2017",

month = sep,

doi = "10.1016/j.bbmt.2017.05.008",

language = "English",

volume = "23",

pages = "1447--1454",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Comparison of Autologous and Unrelated Transplants for Cytogenetically Normal Acute Myelogenous Leukemia

AU - Mizutani, Motonori

AU - Takami, Akiyoshi

AU - Hara, Masahiko

AU - Mizuno, Shohei

AU - Yanada, Masamitsu

AU - Chou, Takaaki

AU - Uchiyama, Hitoji

AU - Ohashi, Kazuteru

AU - Miyamoto, Toshihiro

AU - Ozawa, Yukiyasu

AU - Imataki, Osamu

AU - Kobayashi, Naoki

AU - Uchida, Naoyuki

AU - Kanamori, Heiwa

AU - Kamimura, Tomohiko

AU - Eto, Tetsuya

AU - Onizuka, Makoto

AU - Tanaka, Junji

AU - Atsuta, Yoshiko

AU - Yano, Shingo

PY - 2017/9

Y1 - 2017/9

N2 - Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P =.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P =.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.

AB - Allogeneic stem cell transplantation (SCT) from an HLA-matched sibling donor (MSD) is a postremission treatment that offers a potential cure for adults with cytogenetically normal (CN) acute myelogenous leukemia (AML) in first complete remission (CR1). The best alternative in the absence of an MSD remains unclear, however. The aim of this study was to retrospectively compare the outcomes of autologous peripheral blood stem cell transplantation (auto-PBSCT; n = 177) and allogeneic bone marrow transplantation (BMT) from an HLA-matched unrelated donor (MUD; n = 173) in adult patients with CN-AML/CR1. Both the multivariate analysis (hazard ratio [HR], 1.18; 95% confidence interval [CI], 0.71 to 1.97; P =.53) and propensity score models (HR, 1.40; 95% CI, 0.80 to 2.43; P =.24) indicated that the leukemia-free survival (LFS) rate of auto-PBSCT was not significantly different from that of MUD-BMT. These results suggest that in the absence of an available MSD, auto-PBSCT remains a viable alternative as postremission therapy in patients with CN-AML/CR1.

UR - http://www.scopus.com/inward/record.url?scp=85021069069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021069069&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.05.008

DO - 10.1016/j.bbmt.2017.05.008

M3 - Article

C2 - 28533061

AN - SCOPUS:85021069069

VL - 23

SP - 1447

EP - 1454

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -